Alpha 2.0
Login Register
» Authors » V H van der Velden

V H van der Velden

Explore the profile of V H van der Velden including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 19
Citations 438
Followers 0
Related Specialties
Allergy & Immunology
Hematology
Oncology
Top 10 Co-Authors
J J van Dongen
H C Hoogsteden
B A Naber
M A Versnel
S E Overbeek
T Szczepanski
P T van Hal
H F Savelkoul
P M Hoogerbrugge
P G Hoogeveen
Published In
Leukemia
Clin Exp Allergy
Cytokine
Eur Cytokine Netw
Br J Haematol
Affiliations
Soon will be listed here.
Recent Articles
1.
High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation
Marshall G, Dalla Pozza L, Sutton R, Ng A, de Groot-Kruseman H, van der Velden V, et al.
Leukemia . 2013 Feb; 27(7):1497-503. PMID: 23407458
Children with acute lymphoblastic leukemia (ALL) and high minimal residual disease (MRD) levels after initial chemotherapy have a poor clinical outcome. In this prospective, single arm, Phase 2 trial, 111...
2.
Minimal residual disease in leukaemia patients
Szczepanski T, Orfao A, van der Velden V, San Miguel J, van Dongen J
Lancet Oncol . 2002 Mar; 2(7):409-17. PMID: 11905735
Because of developments in diagnosis of haemopoietic malignant diseases during the past two decades, routine and reliable identification of very low numbers of malignant cells, known as minimal residual disease...
3.
Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia
van der Velden V, Joosten S, Willemse M, van Wering E, Lankester A, van Dongen J, et al.
Leukemia . 2001 Aug; 15(9):1485-7. PMID: 11516112
No abstract available.
4.
T-lymphocytes in bone marrow samples of children with acute lymphoblastic leukemia during and after chemotherapy might hamper PCR-based minimal residual disease studies
van Wering E, van der Velden V, Szczepanski T, van Dongen J
Leukemia . 2001 Aug; 15(8):1301-3. PMID: 11480575
No abstract available.
5.
Clearance of maternal leukaemic cells in a neonate
van der Velden V, Willemse M, Mulder M, Szczepanski T, Langerak A, Wijkhuijs J, et al.
Br J Haematol . 2001 Jul; 114(1):104-6. PMID: 11472352
A 36-week pregnant woman was diagnosed with acute lymphoblastic leukaemia. Delivery was initiated prematurely, and a healthy child was born. Cord blood and peripheral blood samples from the neonate (obtained...
6.
Selective development of a strong Th2 cytokine profile in high-risk children who develop atopy: risk factors and regulatory role of IFN-gamma, IL-4 and IL-10
van der Velden V, Laan M, Baert M, de Waal Malefyt R, Neijens H, Savelkoul H
Clin Exp Allergy . 2001 Jul; 31(7):997-1006. PMID: 11467989
Background: The immunological processes in early life and their relation to allergic sensitization leading to a Th2 cytokine profile are still not well understood. Objective: To analyse the environmental and...
7.
Low frequency of reverse transcription polymerase chain reaction-detectable chromosome aberrations in relapsed acute myeloid leukaemia: implications for detection of minimal residual disease
van der Velden V, Schoch C, Langerak A, Schnittger S, Hoogeveen P, van Dongen J
Br J Haematol . 2001 Jul; 113(4):1082-3. PMID: 11442511
No abstract available.
8.
Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells
van der Velden V, Te Marvelde J, Hoogeveen P, Bernstein I, Houtsmuller A, Berger M, et al.
Blood . 2001 May; 97(10):3197-204. PMID: 11342449
Antibody-targeted chemotherapy is a promising therapy in patients with acute myeloid leukemia (AML). In a phase II study of Mylotarg (CMA-676, gemtuzumab ozogamicin), which consists of a CD33 antibody linked...
9.
CD13/aminopeptidase N involvement in dendritic cell maturation
van der Velden V, Leenen P, Drexhage H
Leukemia . 2001 Mar; 15(1):190-1. PMID: 11243392
No abstract available.
10.
Human keratinocytes are major producers of IL-18: predominant expression of the unprocessed form
Companjen A, van der Velden V, Vooys A, Debets R, Benner R, Prens E
Eur Cytokine Netw . 2000 Oct; 11(3):383-90. PMID: 11022122
The cytokine network in the skin is a tightly regulated system in which IL-1 isoforms, as well as their receptors and antagonists have a central role. The recently discovered IL-1...